About o2h group
o2h group is a venture capital firm founded in 2005. It is primarily based out of Cambridge, United Kingdom. As of Nov 2023, o2h group has invested in 11 companies. It primarily invests in Seed round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of ViaNautis A lot of funds co-invest with o2h group, with names like Jonathan Milner sharing a substantial percentage of its portfolio. o2h group has team of 33 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
o2h group's List of Top Investments
o2h group has a portfolio of 11 companies. Their most notable investments include Turbine and Pencil Biosciences.Their portfolio spans across United Kingdom, Hungary and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 2 other sectors, across stages such as Seed, Series A stages. Here is the list of top investments by o2h group:1. Turbine
Provider of an AI based cancer therapy management software for researchers and doctors. Turbine's Simulated Cell is made of a network, including proteins and their physical and conditional relations. It can be customized with multiple OMICS layers to simulate any cancer type. The model is further treated with all likely treatment combinations in silico with the help of AI algorithms to find the optimal drug combination.
Key facts about Turbine
- Founded Year: 2015
- Location: Budapest (Hungary)
- Stage: Series B
- Total Funding till date: $61.7M
- Employee Count: 116 as on Jul 31, 2026
- Investors: Accel, MassMutual Ventures and 19 Others
- Latest Funding Round: Series B, Feb 24, 2026, $*****
- Highlight: Editors' Pick
Pencil Biosciences is a provider of gene-editing technology. It is developing an innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases.
Key facts about Pencil Biosciences
- Founded Year: 2018
- Location: Alderley Edge (United Kingdom)
- Valuation: $*****
- Stage: Seed
- Total Funding till date: $10.4M
- Employee Count: 17 as on Jul 31, 2026
- Investors: Martlet Capital, EMV Capital and 16 Others
- Latest Funding Round: Seed, Aug 16, 2023, $*****
- Highlight: Editors' Pick
3. ViaNautis
Developer of targeted nanomedicines for drug delivery. The company utilizes proprietary technology "polyNaut" that can be formulated to encapsulate a wide array of genetic cargoes for viral and non-viral delivery for CNS diseases and cystic fibrosis.
Key facts about ViaNautis
- Founded Year: 2018
- Location: Cambridge (United Kingdom)
- Stage: Series A
- Total Funding till date: $25M
- Employee Count: 46 as on Jul 31, 2026
- Investors: Origin Capital, 4Bio Capital and 7 Others
- Latest Funding Round: Series A, Nov 13, 2023, $*****
- Highlight: Editors' Pick
4. Spirea
SPIREA is a developer of therapeutic solutions for cancer treatments. It has developed antibody-drug conjugate therapeutics to revolutionize cancer treatment and improve the lives of patients. It combines cytotoxic drug payload with the targeting ability of an antibody that is targeted to kill cancer cells.
Key facts about Spirea
- Founded Year: 2016
- Location: Harrogate (United Kingdom)
- Stage: Seed
- Total Funding till date: $2.93M
- Employee Count: 8 as on Jul 31, 2026
- Investors: University of Cambridge, ACF Investors and 12 Others
- Latest Funding Round: Seed, Jun 14, 2022, $*****
Developer of targeted treatments for the treatment of psychiatry and neurological diseases. The company focuses on two main treatments targeting cognitive impairment associated with schizophrenia and neuroinflammation, using novel formulations of well-characterized CNS-active small molecules.
Key facts about Monument Therapeutics
- Founded Year: 2019
- Location: Macclesfield (United Kingdom)
- Stage: Seed
- Total Funding till date: $5.98M
- Employee Count: 5 as on Jul 31, 2026
- Investors: ACF Investors, Cambridge Angels and 26 Others
- Latest Funding Round: Seed, Feb 25, 2025, $*****
- Highlight: Editors' Pick
o2h group's Year-on-Year Investment Trends
o2h group has invested in 11 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. Its most recent first time investment was in ViaNautis.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
2020 | 0 | 0 | 0 |
2019 | 1 | 0 | 1 |
o2h group's Investments by Stage
o2h group has made 4 investments in Seed stage with an average round size of $3.29M and 1 investment in Series A stage with an average round size of $25M.Stage of entry | No. of Investments |
|---|---|
Seed | 4 |
Series A | 1 |
Note: We have considered here, only first round of investments
o2h group's Investments by Sector
o2h group has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Artificial Intelligence - Industry Applications, Enterprise Applications and HealthTech. Notably, it has invested in 10 Enterprise (B2B) companies, 8 Tech companies, 3 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 4 |
High Tech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Enterprise Applications | 1 |
HealthTech | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
o2h group's Investments by Geography
o2h group has made most investments in United Kingdom (4), followed by Hungary where it has made 1 investment.Country | No. of Investments |
|---|---|
United Kingdom | 4 |
Hungary | 1 |
Note: We have considered here, only first round of investments
o2h group's recent investments
o2h group has not made any investment in 2026 so far.Here are the most recent investments by o2h group:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 13, 2023 | United Kingdom | Series A | 2187 | [+6] | |
Jun 14, 2022 | United Kingdom | Seed | 3125 | [+5] | |
Sep 28, 2021 | United Kingdom | Seed | 4954 | [+5] | |
Jan 07, 2021 | Hungary | Seed | 6107 | [+4] | |
Dec 11, 2019 | United Kingdom | Seed | 3409 |
Team profile of o2h group
o2h group has a team of 33 members including 3 Partners and 6 Principals located in India and United Kingdom. o2h group's team does not sit on the board of any company as of now.Here is a list of top team members in o2h group:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Cambridge | |||
Partner | Congleton | - | ||
Partner | Ahmedabad | - | ||
Principal | London | - | ||
Principal | Ahmedabad | - | ||
Principal | Ahmedabad | - | ||
Principal | Ahmedabad | - | ||
Principal | Ahmedabad | - | ||
Principal | Ahmedabad | - |
Co-investors of o2h group
Over the past 7 years, 45 investors have co-invested in o2h group's portfolio companies. This includes funds and angels.
- Invested before o2h group: o2h ventures, Delin Ventures and 7 others have invested in rounds before o2h group. There are 2 companies where o2h ventures has invested before o2h group and 1 company where Delin Ventures has invested before o2h group.
- Top Co-investors of o2h group: 22 investors entered a company along with o2h group. These include investors like Jonathan Milner (2 companies).
- Invested after o2h group: A total of 14 investors have invested in o2h group's portfolio after their investments. Top Investors include Accenture (1 company), MassMutual Ventures (1 company) and Day One Capital (1 company).
Recent News related to o2h group
•
OutSee Closes £2.5M Seed Funding RoundFinSMEs•Jan 13, 2026•OutSee, Empirical Ventures, Kadmos Capital, Panacea Venture and 2 others
•
o2h Group Celebrates 20 Years with Thought-Provoking Panel Discussions at 7th o2h Collaborative Innovation ConferenceAsian News International•Mar 06, 2025•o2h group
•
Rare Disease Biotech Raises $47m Series C, Plans For Phase 2 Trial EndPoints News•Aug 01, 2024•Healx, R42 Group, Atomico, Balderton Capital and 6 others
•
•
Research into effective lung fibrosis treatment receives funding boostPharma Business International•Aug 02, 2022•o2h group, Alevin Therapeutics
•
Prominent backers invest in biotech spin-outInsider Media•Jun 15, 2022•R42 Group, ACF Investors, o2h group, Syndicate Room and 1 other
•
Spirea raises £2.4m to develop cancer treatmentBdaily•Jun 14, 2022•Spirea, Cambridge Enterprise, R42 Group, ACF Investors and 5 others
•
Oxford Drug Design secures £2.2m in bridge round commitments from existing investors and angelsPrivate Equity Wire•May 19, 2022•Oxford Drug Design, ACF Investors, o2h ventures, Meltwind Advisory and 2 others
•
Diagnostics startup raises cash to grow innovation engineBusiness Weekly newspaper•Oct 06, 2021•Sanome, Heal Capital, Crista Galli Ventures, Selvedge Venture and 2 others
•
Sanome raises £2m to drive forward clinically validated home testing using combination biomarkersCambridge Network•Sep 30, 2021•Sanome, Heal Capital, Crista Galli Ventures, Selvedge Venture and 2 others
